Supplementary Figure 1 from HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine

August 1, 2025

View at Publisher

Ask AI

Bookmark

Share

Key Points

Main finding shows that including HER1 and HER2 in vaccine formulations can boost antitumor effects against targeted cells.
Key evidence indicates the combination of HER proteins significantly enhances the efficacy of the HER3-specific monovalent vaccine.
Approach involved using recombinant HER protein antigens in various vaccine formulations to assess immune responses.
Significance lies in the potential improvement of cancer vaccines, making treatments more effective for patients with HER-driven tumors.

Answers are grounded in this paper and cite their sources.

Supplementary figure reveals enhanced antitumor effects by combining HER1 and HER2 with a HER3-specific vaccine, highlighting antibody interactions.

Amino acid sequences of the recombinant HER1, HER2, and HER3 proteins used as antigens in the Mv-H3, Bv-H3/H2, and Tv-H3/H2/H1 vaccine formulations.

No takes yet. Share an insight, caveat, or question.

Bermúdez-Abreut et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share